Abstract
Advanced RCC has seen many treatment advances in the last several years, with the introduction of many novel therapies. Recent evidence from the KEYNOTE 426 and CheckMate 214 studies has mandated a rearrangement of treatment algorithms for advanced clear-cell RCC. We now await both clinical experience and prospective clinical trials to help inform the optimal sequence of therapy with these newer therapies, VEGF-targeted therapies and other evidence-based options. Ongoing participation in research and clinical trials to further our knowledge in this field continues to be an essential priority for healthcare professionals with an interest in advanced RCC. Therapy should be individualized based on patient profiles and disease characteristics, and each agent chosen should be optimized to obtain best results, with multidisciplinary care being paramount in achieving maximal benefit for patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
